华贞生物医药科技有限公司.doc

1、华贞生物医药科技有限公司
华贞生物医药科技有限公司由赵子建博士和戴一凡博士两位千人计划获得者共同创建。自2010年成立以来,华贞公司充分利用赵博士和戴博士在各自研究领域的丰富经验,主要集中研发和生产生物科技研发所用的检测试剂含抗体和高通量检测试剂盒,以及治疗肥胖、糖尿病、脂代谢紊乱和癌症的生物类药物。
公司划分为华贞生物科技和华贞生物医药两个主要部门。华贞生物科技主要研发和生产生物医药开发-转录因子活性快速检测试剂盒及生物医药科研用的抗体。华贞公司的生物医药部门最近成功研发了利用基因工程改造的双歧杆菌表达治疗肥胖和脂代谢紊乱的多肽药物的技术平台。华贞公司将利用此项技术,开发一系列有自主知识产权的治疗肥胖和糖尿病的多肽药物。
The SinoGen Biopharmaceutical Inc. (“SinoGen”) was established in 2010 with a primary strategy of developing patented propriety drugs towards the treatment of obesity, dyslipidemia and cancer. It was co-founded in Nanjing by two US expatriates Drs. Allan Zhao and Yifan Dai who both were awarded National “1000 Plan” in the Scientific Park District Jiangning Special Economic Zone in Nanjing. Based on the two co-founders’ profound experience,the SinoGen mainly focus on R & D and production of biotechnology test kits containing antibodies and high-throughput detection kit, as well as the treatment of obesity, diabetes, lipid metabolism disorders and cancer biology drug.
The SinoGen was divided into two parts: the SinoGen biological science & technology and the SinoGen biological pharmacy. The SinoGen biological science & technology mainly research, develop and produce transcription factor activity assay kit, and biomedical research with antibodies. Rapid quantitative determination of the transcription factor activity in disease research and development of new drugs have very important significance for understanding the regulation of gene expression. The SinoGen biological pharmacy recently essfully developed a Bifidobacterium using of ically engineered to express the treatment of obesity and metabolic disorder in the peptide drug technology platform. The SinoGen will use this technology to develop a series of peptide drugs of obesity and diabetes with independent intellectual property owned by Dr. Zhao Zijian.
2、柯菲平医药有限公司
柯菲平医药有限公司成立于2002年,目前已发展为集新药销售、生产、研发、医药软件开发为一体的高科技创新型医药企业。营业额以每年60%以上的速度增长。,并且销售利润高于行业平均水平。公司产品“诺新康”覆盖全国近8000家医疗单位,已